The combination of disease-modifying anti-rheumatic drugs (DMARDs) and the development of tumor necrosis factor (TNF) inhibitors have for the first time lead to a clinical remission of RA and induce a delay or complete stop of the clinical and radiological progression of the disease, thus improving the quality of life of many patients with RA [4]. Here, TNF is linked to rheumatoid arthritis.